Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Headquarters
Denmark
Address
Novo Alle 1, Bagsvaerd, 2880
Website
www.novonordisk.com
Telephone
45 44 448888
No of Employees
49,295
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NOVO B (CPH)
Revenue (2021)
$22.4B
10.9%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
13.3%
(2021 vs 2020)
Market Cap*
$187.9B
Net Profit Margin (2021)
XXX
2.2%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Diabetes Delivery Systems: | Tresiba |
| Insulin pens | Ryzodeg |
| Pre-filled insulin delivery systems | Xultophy |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In May, the company and Flagship Pioneering entered into a collaboration to create a portfolio of transformational medicines. |
| 2022 | Others | In March, Novo Nordisk Foundation awarded grants of DKK 8.8 billion for scientific, humanitarian and social causes. |
| 2022 | Contracts/Agreements | In March, the company and Health2Sync entered into a partnership to help patients undergoing insulin therapy wirelessly transfer dose logs to a mobile health app. |
Competitor Comparison
| Key Parameters | Novo Nordisk AS | Johnson & Johnson | Pfizer Inc | F. Hoffmann-La Roche Ltd | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | Denmark | United States of America | United States of America | Switzerland | Switzerland |
| City | Bagsvaerd | New Brunswick | New York | Basel | Basel |
| State/Province | - | New Jersey | New York | - | - |
| No. of Employees | 49,295 | 141,700 | 79,000 | 100,920 | 110,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Helge Lund | Chairman | Executive Board | 2018 | 60 |
| Lars Fruergaard Jorgensen | President; Chief Executive Officer | Executive Board | 2017 | 56 |
| Karsten Munk Knudsen | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 51 |
| Marcus Schindler | Head - Research & Early Development; Executive Vice President; Chief Scientific Officer | Senior Management | 2021 | 56 |
| Jeppe Christiansen | Vice Chairman | Executive Board | 2013 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer